Disease Targets

Addressing Complex Diseases with Critical Unmet Needs

Royality Med Pharmaceuticals Group (RMPG) is committed to tackling diseases that involve multiple, interconnected biological processes throughout the body. Although current treatments target certain aspects of these diseases, they do not sufficiently address their complex and multifactorial nature, which leaves significant gaps in effective care.

Systemic Sclerosis

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation followed by fibrosis of the skin, blood vessels, and internal organs. This progressive condition substantially reduces quality of life and often leads to premature mortality. No therapies are currently approved specifically for systemic sclerosis. Existing treatments mainly address the inflammatory symptoms, offering partial relief but failing to stop disease progression. To truly benefit patients, it is essential to also target fibrosis and vascular damage. Our candidate therapy for systemic sclerosis has the potential, based on its mechanism of action, to slow, halt, or even reverse the course of the disease.

Multiple Sclerosis

Multiple sclerosis (MS) is marked by the breakdown of the protective myelin sheath surrounding nerve fibers, impairing nerve signal transmission. This demyelination is driven by autoimmune inflammation. Current treatments primarily focus on reducing inflammation or suppressing the immune system, which provide symptom relief but often come with significant side effects. Meaningful impact requires therapies that intervene early in the disease process to reduce inflammation, regulate autoimmunity without harmful immunosuppression, and prevent or slow demyelination.

RMPG’s investigational drug targets key physiological pathways responsible for MS, aiming to slow, stop, or potentially reverse disease progression while minimizing adverse effects.

Parkinson’s Disease

Parkinson’s disease (PD) presents with symptoms including tremors in the hands, arms, legs, and face; muscle stiffness; slowed movement (bradykinesia); and difficulties with balance and coordination. Drug development has largely focused on the dopaminergic system, which offers only temporary and partial symptom relief. Attempts at neuroprotection have yet to succeed.

Current therapies mainly address motor symptoms but do not adequately treat non-motor symptoms, which often appear earlier and significantly reduce patient quality of life. There is a need for comprehensive treatment strategies that utilize multiple mechanisms of action beyond the dopaminergic pathway.

Huntington’s Disease

Huntington’s disease (HD) is a rare genetic neurodegenerative disorder characterized by a combination of motor impairment, cognitive decline, and psychiatric disturbances. While current medications can help manage symptoms such as movement difficulties and psychiatric issues, no therapy currently changes the disease’s progression. To improve patient outcomes, it is crucial to enhance quality of life by alleviating symptoms and supporting independence, while also striving to slow disease advancement.